NCT06765876View on ClinicalTrials.gov

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: a Dose Escalation Phase I Trial

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 23, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Leukemia, Myeloid, Acute(AML)Precursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic Syndromes (MDS)Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Interventions
BIOLOGICAL

Autologous CAR123 T lymphocytes

Anti-CD123 Chimeric Antigen Receptor (CAR) T-Cells (CART123)

Trial Locations (1)

12800

RECRUITING

Ustav hematologie a krevni transfuze / Institute of Hematology and Blood Transfusion, Prague

All Listed Sponsors
lead

Institute of Hematology and Blood Transfusion, Czech Republic

OTHER